From February 27 to 28, Xu Jinghe, CPC Leading Group Member and Deputy Director of the NMPA, carried out an investigation in Shijiazhuang to learn how the construction of medical device review and approval capacities was enhanced at provincial level. He visited Shijiazhuang International Biomedical Park, Hebei Ruihe Medical Device Co., Ltd., GenSure Biotech Inc. and Hebei Puni Medical Technology Co., Ltd. to know the requirements of industrial innovation and high-quality development, and heard the reports on drug safety consolidation and improvement actions in Hebei Province.
While fully affirming the regulation efforts of Hebei administration, Xu Jinghe stressed that more efforts should be made to overall plan the high-level safety and high-quality development, strengthen the construction of Category II medical device review and approval capacities, perfect the review and approval system and practically ensure the safe use of medical devices by the public; that relevant requirements on drug safety consolidation and improvement actions and the issue-oriented mode should be followed to comprehensively investigate and address potential risks, maintain a tough stance, severely punish the violations against laws and regulations, lay a solid foundation, comprehensively strengthen the construction of regulation capacity and build a solid bottom line of drug safety in an all-round manner.
Source: National Medical Products Administration
While fully affirming the regulation efforts of Hebei administration, Xu Jinghe stressed that more efforts should be made to overall plan the high-level safety and high-quality development, strengthen the construction of Category II medical device review and approval capacities, perfect the review and approval system and practically ensure the safe use of medical devices by the public; that relevant requirements on drug safety consolidation and improvement actions and the issue-oriented mode should be followed to comprehensively investigate and address potential risks, maintain a tough stance, severely punish the violations against laws and regulations, lay a solid foundation, comprehensively strengthen the construction of regulation capacity and build a solid bottom line of drug safety in an all-round manner.
Source: National Medical Products Administration